It showed sub-nanomolar affinity to BCL-2 (Ki < 0.010 nM) with antitumor activity against non-Hodgkin’s lymphoma (NHL) [63], CLL [64], and acute leukemias [65, 66] in vitro. The gene discussed is BCL2; the disease is non-Hodgkin lymphoma.